News and Announcements
Proteomics PromarkerD Development Advances in China
- Published June 14, 2016 2:06PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
14th June 2016, ASX Announcement
Highlights:
- PILL and its Chinese partner Newsummit Biopharma have secured funding towards development for an In vitro Diagnostic (IVD) kit for PromarkerD in China.
- Chinese patent granted for PromarkerD as a predictive and diagnostic test for diabetic kidney disease.
- Initial tranche of funding under the PILL-NSB agreement will support the first stage of PromarkerD IVD kit manufacture.
- China is a key global market for PILL – WHO estimates 120m Chinese have diabetes and are at risk of kidney disease.
Life sciences company Proteomics International Laboratories Ltd (ASX: PIQ) (the Company, PILL) is pleased to announce significant advances towards commercialisation of PromarkerD as an In vitrro Diagnostic (IVD) test in China, with the grant of a key patent and funds secured to initiate kit manufacture.
To view the full announcement, please click on the button below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
